Jump to content

JMH03

Member
  • Posts

    1143
  • Joined

  • Last visited

Everything posted by JMH03

  1. JMH03

    MEY

    Can only be stronger once reserve upgrade is in the light of day! I wonder whether there will be any detail on HOA, or JV with Areva.
  2. JMH03

    MEY

    TRADING HALT pending announcement re namibia project. Here comes the resource upgrade
  3. JMH03

    MEY

    indeed, soaking up stock around the 15.5c to 16c level a promising sign heading into the news.
  4. JMH03

    AOE

    looks like they were acting as prime brokers for Mathews Capital.
  5. JMH03

    AOE

    Deutsche takes 5.9% of AOE. Fin Review Street Talk speculates could be acting on behalf of Chinese. Would love to see a bidding war bewtween Shell and Chinese
  6. JMH03

    AOE

    Deutsche takes 5.9% of AOE. Fin Review Street Talk speculates could be acting on behalf of Chinese. Would love to see a bidding war bewtween Shell and Chinese
  7. JMH03

    AZO

    you may get a chance to pick some up low to mid 50's on Monday
  8. JMH03

    BOW

    STO just announced 19.9% stake in ESG for $170mil valuing ESG >$1. should light a spark under BOW share price again tmrw
  9. JMH03

    MEY

    Stephen Dattels' Polo Resources is busy expanding its interests in southern African uranium explorers, taking significant stakes in Impact Minerals and West Australian Metals. Author: Lawrence Williams Posted: Friday , 05 Jun 2009 LONDON - We recently reported here the moves being made by Stephen Dattels, and some of the companies with which he is associated, stake building in exciting Namibian uranium developer, Extract Resources (see Dattels hitting Rossing South uranium play on five fronts). But Extract is not Dattels' only foray into southern African uranium projects as he, and associated company Polo Resources, are busy tying down stakes in other significant uranium prospects in the region. With other companies in the Dattels stable also capable of stakebuilding in the sector, one does get the impression that Dattels himself, who made a fortune selling UraMin to Areva at the height of the uranium price boom in 2007, does have a certain confidence in the future of the uranium market! The latest two uranium sector investments in this pattern to emerge are in Australian headquartered companies Impact Minerals (ASX:IPT) and West Australian Metals (ASX:WME), both of which have significant uranium exploration projects in the region - the former in Botswana and the latter in Namibia - both considered good countries to work in from a mining friendly and political risk standpoint. In an announcement this morning, Impact noted that it is placing 18,668,326 new shares at an issue price of 16.07 cents per share, raising $3 million, to Polo Resources (AIM:PRL) bringing Impact's cash reserves to $4.3 million. Polo will hold a 19.9% equity interest in Impact following the completion of the placement. Impact goes on to throw further light on the depth of Polo's interests in the sector saying that its primary focus is investment in, or acquisition and development of, advanced stage uranium mining projects and that it currently has an investment portfolio of uranium and coal interests, and 50% of a joint venture with Peabody Energy Corporation, formed to hold all of Polo's coal and uranium assets in Mongolia. During 2009, Polo has so far acquired an 8.93% interest in Berkeley Resources, a leading uranium explorer doing feasibility work on the Salamanca deposit in Spain; a 9.08% interest in Extract Resources, operator of the Rossing South project in Namibia; and has also entered into a Subscription Agreement to acquire up to a 19.9% interest in A-Cap Resources, currently undertaking feasibility work on the Letlhakane uranium project in Botswana. Impact also noted that Polo's Executive Chairman, Stephen R Dattels, and MD, Neil Herbert, were both UraMin directors who negotiated the sale of UraMin to Areva in July 2007 for US$2.5 billion. The flagship deposit of the UraMin assets was the world class Trekkopje calcrete-hosted uranium deposit in Namibia. Impact owns 100% of its Botswana Uranium Project which comprises about 25,000 sq km of Prospecting Licences that cover about 350 km of the strike extensions of rocks that host uranium deposits near the town of Serule. Here A-Cap Resources has its Letlhakane uranium project comprising three deposits hosted by near-surface calcrete and by Karoo Group sedimentary rocks. A-Cap has reported an inferred resource of 98 million lbs uranium oxide at an average grade 158 ppm at a cut-off grade of 100 ppm. Meanwhile, yesterday, West Australian Metals announced that it has secured Polo as a ‘cornerstone investor' in a previously announced $9.9 million share placement. Polo is to take up 49.56 million shares (and attaching options) under the placement, which will involve the issue of a total of 82.6 million shares at an issue price of $0.12 each. The balance of the placement is to be subscribed for by institutional or sophisticated investors. Upon completion of the placement Polo will own approximately 11.95% of the shares on issue. And - among the ‘sophisticated investors' are four of Polo's directors: Stephen Dattels, Neil Herbert and Paul Ingram subscribed for 2.25 million shares while Guy Elliott subscribed for 1 million shares. In a statement on this transaction, Neil Herbert said "We are very pleased to announce the further expansion of our uranium interests with this significant investment in WME. We are particularly excited by the potential of the Marenica Project which we see as a considerable value driver for shareholders ... The Marenica project lies within the same uranium province as the Rossing and Langer Heinrich uranium mines and immediately north of the Trekkopje mine, which is currently being developed by Areva." While Canada, Kazakhstan and Australia are currently seen as the world's largest uranium producers and as having the biggest reserves, southern Africa - including Namibia, Botswana and South Africa - look like in combination as likely to challenge the pre-eminence of the current top uranium miners. One gets the impression that the explorers have only scratched the surface of this region so far, but maybe too many new miners coming on stream over the next decade could lead to a glut in the market.
  10. Noble increased its cash bid for GCL to $7 Friday night. WHC should respond well on this news.
  11. JMH03

    GCL

    Noble increased cash bid to $7 on Friday night. All coal stocks to soar on Monday
  12. Well we saw it rally 40% on the back of that news settling back at $1.18 on the close. Though this stock is still very much under the radar and trades on thin vol. The company has all the makings of a 4-5 bagger from current levels. Distribution through one of the global giants Johnson and Johnson, and their Patent goes all the way to 2020. It is my understanding Johnson and Johnson/Lifescan have 6-8 of their employees working full time at UBI premises.
  13. Universal Biosensors signs blood glucose diagnostic product agreements with LifeScan, Inc. $25mil in revenue 2009, $28mil cash in bank and market cap of $140mil?
  14. Wilson HTM have increased their 12 month price target to $4.83 based on reimbursement of $11,500 per patient for CF. And this still assumes $7,500 per patient for the bronch patients (ie room for further upgrades to assumptions pending further trial results in that market).
  15. Pharmaxis positive over Bronchitol trial AAP 2009-05-04 Drug developer Pharmaxis Ltd says an international Phase III clinical trial of its compound Bronchitol to determine whether it would improve lung function in people with cystic fibrosis has produced positive results. "The clinical trial comfortably met this endpoint," Pharmaxis said in a statement on Monday. Pharmaxis said consistent loss of lung function is the leading cause of death for people with cystic fibrosis. Bronchitol is designed to hydrate the airway surface of the lungs, and promote normal clearance of mucus. Pharmaxis said patients treated with Bronchitol had a statistically significant improvement in lung function. The trial also showed that Bronchitol further improved lung function in patients already being treated with the most commonly used cystic fibrosis therapeutic, Pulmozyme. "We are delighted that Bronchitol performed so well in this important long-term study, and we now know that it can change the therapeutic landscape for many of the 75,000 people with this disease," Pharmaxis chief executive Dr Alan Robertson said. "As the first dry powder formulation to publish positive results in cystic fibrosis, it promises convenience for patients who have complex daily schedules dominated by difficult treatment regimens." The trial involved 324 patients and was conducted in 40 centres in the United Kingdom, Ireland, Australia and New Zealand. Pharmaxis said Bronchitol was well tolerated overall and had a favourable safety profile. The company will file a marketing application later this year, with the objective of obtaining authorisation for Bronchitol to be used in the treatment of cystic fibrosis in Europe and elsewhere. The first scientific presentation of the trial results will be made at European Cystic Fibrosis Society meeting in France in June. Dr Robertson said Pharmaxis hoped to have Bronchitol approved during the third quarter of next year and on the market soon thereafter. Dr Robertson said Pharmaxis would probably market Bronchitol itself. "We have tenaciously and fiercely held on to the rights, particularly for this asset, which we think is our most valuable asset at the moment," he told AAP. Dr Robertson said Bronchitol had the potential to "transform" the company. Pharmaxis shares were in a trading halt on Monday after last trading at $2.28. Trevor Chappell
  16. Fantastic news. Well done to the company and all the patient long-term holders who will be repaid in multiples from these levels over the next two years. Tmrw should see $2.70-$3.00 range
  17. trading halt pending announcement. If these results are positive watch it fly obviously the reverse is also applicable.
  18. gross margins of 90%
  19. I think the two bullet points from the latest Wilson HTM note should cover that concern; The major value accretion event for the company is the announcement of the initial stage of the first CF Phase III trial by the end of April. (MEANING ANY DAY NOW) The share is already rallying strongly in the face of this result. Reimbursement for Bronchitol in Europe would be around US$13,000 per patient p.a., if the result shows Bronchitol to be only as good as Pulmozyme. Assuming only 30% of the estimated 20,000 patients in Europe use the drug, this translates into annualised revenues of around $100M.
  20. phase three results coming up this month. If the results are strong, analysts may start to plug $15,000 per patient into their models rather than $7,500 and hey presto
  21. JMH03

    GCL

    Noble have bid $4.85 cash. This could stir up the whole sector again. Keep an eye on WHC, MCC and FLX today
  22. JMH03

    PES

    I doubt Shell will let this go to BG..... I think there is a high probability of Shell bidding for AOE in response to BG's bid for PES - which will see the cash + scrip bid for PES then eclipse the $6.40 cash offer.
  23. In reply to: JMH03 on Friday 02/01/09 09:40am some large bids on the screen early - and they were happy to pay up yesterday.
  24. This is one coal stock worth a look - given the likes of GCL/MCC/FLX have all found a floor. Japs recently paid agreed to A$370mil for 22.5% stake in Narrabri project alone....that is not much less than the total market cap! If someone is runnign the ruler over FLX, I would imagine WHC would be a close second.....especially with management experience (took Excel coal through from float price of $2 to takeover around $8)
  25. JMH03

    AOE

    In reply to: HDW04 on Sunday 26/10/08 08:25pm Well done H BOB is back!ha The whole sector should fire tmrw. Hope all is well with u and the missus.
×
×
  • Create New...